An investor piece argues three drugs in Lilly's pipeline, rather than Zepbound, could drive the company's next stock gains.
Recap by typeshit. Full story at The Globe and Mail.
BMO's Evan Seigerman expects US share losses to weigh on Ozempic sales, while the 25% CagriSema figure comes from a post-hoc subgroup, not the full trial's 22.7%.
Beauty companies are reportedly exploring products aimed at facial changes linked to rapid weight loss on GLP-1 drugs.
A search page for retatrutide news with no specific story attached, so there is little new beyond recent coverage.
2:06:48
A live Q&A stream from DOWNSIZED taking viewer questions about GLP-1 medications, including Zepbound, Wegovy and Foundayo.
A short primer from @armykalsi on peptides as amino acid chains that carry signals between cells, plus a pitch for treating the whole body.
An investor piece arguing that three of Lilly's pipeline drugs, not Zepbound, could drive the stock's next move. The drugs are named in the full story.
Loading…